| Title: |
Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. |
| Authors: |
Vantyghem, Marie-Christine, Chetboun, Mikael, Gmyr, Valéry, Jannin, Arnaud, Espiard, Stéphanie, Le Mapihan, Kristell, Raverdy, Violeta, Delalleau, Nathalie, Machuron, François, Hubert, Thomas, Frimat, Marie, Van Belle, Eric, Hazzan, Marc, Pigny, Pascal, Noel, Christian, Caiazzo, Robert, Kerr-Conte, Julie, Pattou, François, Members of the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis |
| Source: |
Diabetes Care; Nov2019, Vol. 42 Issue 11, p2042-2049, 8p, 2 Charts, 2 Graphs |
| Subject Terms: |
TYPE 1 diabetes, KIDNEY transplantation, ISLANDS of Langerhans, PANCREAS transplantation, COHORT analysis, METABOLIC regulation, RECEPTOR antibodies |
| Geographic Terms: |
EDMONTON (Alta.) |
| Abstract: |
Objective: The long-term outcome of allogenic islet transplantation is unknown. The aim of this study was to evaluate the 10-year outcome of islet transplantation in patients with type 1 diabetes and hypoglycemia unawareness and/or a functioning kidney graft.Research Design and Methods: We enrolled in this prospective parallel-arm cohort study 28 subjects with type 1 diabetes who received islet transplantation either alone (ITA) or after a kidney graft (IAK). Islet transplantation consisted of two or three intraportal infusions of allogenic islets administered within (median [interquartile range]) 68 days (43-92). Immunosuppression was induced with interleukin-2 receptor antibodies and maintained with sirolimus and tacrolimus. The primary outcome was insulin independence with A1C ≤6.5% (48 mmol/mol). Secondary outcomes were patient and graft survival, severe hypoglycemic events (SHEs), metabolic control, and renal function.Results: The primary outcome was met by (Kaplan-Meier estimates [95% CI]) 39% (22-57) and 28% (13-45) of patients 5 and 10 years after islet transplantation, respectively. Graft function persisted in 82% (62-92) and 78% (57-89) of case subjects after 5 and 10 years, respectively, and was associated with improved glucose control, reduced need for exogenous insulin, and a marked decrease of SHEs. ITA and IAK had similar outcomes. Primary graft function, evaluated 1 month after the last islet infusion, was significantly associated with the duration of graft function and insulin independence.Conclusions: Islet transplantation with the Edmonton protocol can provide 10-year markedly improved metabolic control without SHEs in three-quarters of patients with type 1 diabetes, kidney transplanted or not. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes Care is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
